RET in non-small cell lung cancer

2 EU-approved indications in non-small cell lung cancer need a RET result: sugemalimab (1st line, metastatic) and selpercatinib (advanced).

Line of therapy

Approved indications, Non-small cell lung cancer
DrugBiomarker requirementRegimenSettingConditions
RET fusion1
Monotherapy
Any line
advanced
Not previously treated with a RET inhibitor
EGFR/ALK/ROS1/RET negative1
No sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations
+ platinum-based chemotherapy
1L
metastatic
None

Tumour-agnostic approvals1

Approved for any solid tumour that carries the alteration, wherever the tumour started.

DrugBiomarker requirementRegimenSettingConditions
RET fusion1
Monotherapy
Any line
advanced
Treatment options not targeting RET provide limited clinical benefit, or have been exhausted; Aged 2 years and older

16 approvals for NSCLC need no biomarker and apply whatever the result. All approvals for NSCLC

See also

Label wording2

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Sugemalimab (Cejemly)
    Cejemly in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations.
  2. Selpercatinib (Retsevmo)
    advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.